Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis

Abstract

Introduction: To date, there have been no head-to-head clinical studies comparing calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the treatment of plaque psoriasis. However, the efficacy of 4 weeks of Cal/BD foam and 8 weeks of HP/Taz lotion has been compared using a matchingadjusted indirect comparison (MAIC) approach. Here, we compare the efficacy and safety of Cal/ BD foam and HP/Taz lotion for up to 52 weeks. Methods: An unanchored MAIC was conducted using individual patient data from the PSO-LONG Cal/BD foam trial and a 52-week, openlabel phase 3 study of HP/Taz lotion (NCT02462083). Key outcomes of interest were Physician's Global Assessment (PGA) success (PGA 0/1 with C 2-point improvement) after 4 or 8 weeks of open-label therapy; the proportion of patients who had body surface area affected (BSA) B 3 after open-label therapy who maintained BSA B 3 to week 52; and adverse events (AEs).Results: After matching, patients were statistically significantly more likely to have PGA success after 4 weeks of Cal/BD foam than after 8 weeks of HP/Taz lotion (84.5% versus 54.4%; p \ 0.01). At week 52, 92.5% and 92.4% of patients receiving proactive and reactive Cal/BD foam, respectively, maintained BSA B 3, compared with 49.3% of those treated with HP/Taz lotion (both p \ 0.01). Treatment-related AEs, AEs leading to withdrawal, and AEs associated with drug application (dermatitis, application site pain, and pruritus) were significantly rarer with Cal/BD foam than with HP/Taz lotion (all p \ 0.01). Conclusions: Cal/BD aerosol foam demonstrated significantly greater efficacy than HP/ Taz lotion, and had a more favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam

Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective

“…The absence of head-to-head trial for ED versus NBP is a challenge for this study. Matching-adjusted indirect comparison (MAIC) analyses have been reported as a new tool for timely comparative effectiveness research [11], and have previously been conducted for effectiveness comparison and cost analysis between different therapies [11][12][13][14][15][16]. This study applied unanchored MAIC to compare the effectiveness of ED versus NBP, based on the individual patient data (IPD) of the TASTE trial (ED) and aggregated data of the NBP trial below.…”

Topical proactive therapy in dermatology. A scoping review

“…Typical steroid-related skin side effects were not observed [40], which could supposedly result from a minimal-dose and intermittent corticosteroid application or the possible modulatory effect of calcipotriene [41]. In matching-adjusted indirect comparison analysis, the calcipotriene-betamethasone dipropionate foam approach showed a greater efficacy and more favourable safety profile than halobetasol propionate-tazarotene lotion therapy [42]. Calcipotriene-betamethasone dipropionate foam seems to be a good candidate for the proactive therapy in psoriasis as it was previously observed to be more effective than the gel-based alternative [43][44][45].…”